Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

Executive Summary

• Fraser Health Authority signed a Clinical Trial Agreement with Arch Biopartners, enabling Royal Columbian Hospital (RCH) to commence patient recruitment for the Phase II LSALT peptide trial targeting cardiac surgery‑associated acute kidney injury.
• RCH becomes the ninth global site and fourth Canadian site activated in the study, expanding the trial’s geographic footprint.
• Additional feasibility discussions are underway with other leading cardiac surgery centres across Canada and the United States, indicating continued pipeline expansion.

Key Details

• Clinical Trial Agreement (CTA): Executed between Arch Biopartners Inc. and Fraser Health Authority to allow RCH participation in the Phase II LSALT peptide trial.
• Regulatory Approvals: RCH has secured final Research Ethics Board approval, operational clearances, and a letter of authorization from Fraser Health.
• Site Activation: RCH is now the ninth site worldwide and fourth in Canada actively recruiting patients for the LSALT peptide study.
• Current Enrolling Sites: Toronto General Hospital (UHN), St. Michael’s Hospital (Unity Health Toronto), and University of Calgary, Cumming School of Medicine continue patient enrollment.
• Pipeline Progress: Arch is pursuing feasibility and start‑up discussions with additional cardiac surgery centres in Canada and the U.S., aiming to broaden trial reach.
• Company Overview (contextual): Arch Biopartners develops therapies for acute kidney injury (AKI) and chronic kidney disease (CKD), with LSALT peptide and cilastatin both in Phase II trials, plus a CKD platform in development.

Notable Quotes

(No direct quotes were provided in the release.)